Biomarkers and precise targeting could help the anti-TGF-β1 antibody SRK-181 succeed where bintrafusp failed, the group hopes.
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Despite unconvincing results so far with next-gen IL-2 agents, plenty of groups are still crowding into this space.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.